Immunologic microenvironment and neoantigen in resected lung primary invasive mucinous adenocarcinoma

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K17772
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55040:Respiratory surgery-related
• Research Institution: Nagoya University
• Principal Investigator: Nakanishi Keita 名古屋大学, 医学部附属病院, 医員 (80868290)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 腫瘍免疫 / 肺腺癌 / 浸潤性粘液腺癌

Outline of Final Research Achievements

During the study period, we analyzed 112 patients with lung adenocarcinoma, 7 patients with invasive mucinous adenocarcinoma among them. Invasive mucinous group showed lower single nucleotide variant and PD-L1 expression, also lower CD8 positive T-cells as well as CD8/CD39/CD103 triple positive T-cells in tumor tissue. In addition, it was shown that expression level of FoxP3, ICOS, LAG3, TIGIT, and CTLA4 were lower comparing to non-mucinous group.

Free Research Field

腫瘍免疫

Academic Significance and Societal Importance of the Research Achievements

Invasive mucinous adenocarcinomaはより免疫抑制的環境にあり、抗腫瘍免疫が働きにくい分子発現プロファイルが認められたことから、これを解除して抗腫瘍T-cellがより働く環境を作り出すことが治療につながる可能性が示唆された。Invasive mucinous adenocarcinomaに特異的なNeoantigenについては現在解析中であるものの、Invasive mucinous adenocarcinomaに対する免疫治療戦略を構築するうえで重要な基礎データが得られたと考えられる。今後、論文発表を通じて社会的な還元を目指していくつもりである。